MCID: TST017
MIFTS: 38

Testicular Malignant Germ Cell Cancer

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases

Aliases & Classifications for Testicular Malignant Germ Cell Cancer

MalaCards integrated aliases for Testicular Malignant Germ Cell Cancer:

Name: Testicular Malignant Germ Cell Cancer 12 15
Malignant Germ Cell Tumor of Testis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5556
NCIt 51 C9063
UMLS 74 C0855197

Summaries for Testicular Malignant Germ Cell Cancer

MalaCards based summary : Testicular Malignant Germ Cell Cancer, also known as malignant germ cell tumor of testis, is related to polyembryoma and malignant sertoli cell tumor. An important gene associated with Testicular Malignant Germ Cell Cancer is SERPINA3 (Serpin Family A Member 3), and among its related pathways/superpathways are Wnt / Hedgehog / Notch and Binding and Uptake of Ligands by Scavenger Receptors. The drugs Cisplatin and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include testis, bone marrow and t cells, and related phenotypes are no effect and Increased shRNA abundance (Z-score > 2)

Related Diseases for Testicular Malignant Germ Cell Cancer

Diseases in the Testicular Germ Cell Cancer family:

Testicular Malignant Germ Cell Cancer

Diseases related to Testicular Malignant Germ Cell Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 141)
# Related Disease Score Top Affiliating Genes
1 polyembryoma 10.5 AFP SERPINA1
2 malignant sertoli cell tumor 10.5 AFP ENO2
3 acinar cell cystadenocarcinoma 10.5 SERPINA1 SERPINA3
4 congenital granular cell tumor 10.4 ENO2 SERPINA1
5 epithelioid leiomyosarcoma 10.4 ENO2 SERPINA3
6 brain germinoma 10.4 AFP POU5F1
7 extragonadal germ cell cancer 10.4 AFP POU5F1
8 scrotal carcinoma 10.4 AFP SERPINA3
9 central nervous system germ cell tumor 10.4 AFP POU5F1
10 embryonal testis carcinoma 10.4 AFP POU5F1
11 endometrial small cell carcinoma 10.4 AFP ENO2
12 intrahepatic bile duct adenoma 10.4 AFP KRT7
13 geniculate herpes zoster 10.4 HP SERPINA1
14 ovarian embryonal carcinoma 10.3 AFP GPC3 POU5F1
15 epstein-barr virus hepatitis 10.3 AHSG ALB
16 gastritis, familial giant hypertrophic 10.3 ALB SERPINA1
17 liver lymphoma 10.3 AFP CEACAM5
18 renal pelvis adenocarcinoma 10.3 AFP KRT7
19 adenosquamous gallbladder carcinoma 10.3 CEACAM5 SERPINA3
20 krukenberg carcinoma 10.3 KRT7 NAPSA
21 eccrine papillary adenocarcinoma 10.3 AHSG KRT7
22 ovary neuroendocrine neoplasm 10.3 CDX2 KRT7
23 seminoma 10.3 AFP ENO2 POU5F1
24 urachal adenocarcinoma 10.3 AFP CEACAM5
25 undifferentiated embryonal sarcoma of the liver 10.3 MDM2 SERPINA3
26 papillary transitional carcinoma 10.3 ENO2 KRT7
27 epithelioid trophoblastic tumor 10.3 KRT7 SALL4
28 appendix adenocarcinoma 10.3 CDX2 KRT7
29 fournier gangrene 10.3 ALB F8
30 small cell carcinoma of the bladder 10.3 ENO2 KRT7
31 sensory organ benign neoplasm 10.3 ENO2 KRT7
32 glandular cystitis 10.3 CDX2 KRT7
33 hematocele of tunica vaginalis testis 10.3 AFP CEACAM5
34 middle ear adenoma 10.3 ENO2 KRT7
35 constrictive pericarditis 10.3 ALB SERPINA1
36 papillary adenoma 10.3 KRT7 NAPSA
37 pancreatic cystadenocarcinoma 10.3 AFP CEACAM5
38 seminal vesicle tumor 10.3 AFP GPC3 KRT7
39 anal paget's disease 10.3 CDX2 CEACAM5
40 gallbladder small cell carcinoma 10.3 ENO2 KRT7
41 ovarian germ cell cancer 10.3 AFP KRT7 SALL4
42 alpha-1-antitrypsin deficiency 10.3 ALB SERPINA1 SERPINA3
43 hepatitis a 10.2 AFP ALB SERPINA1
44 cystadenofibroma 10.2 AFP KRT7 SERPINA1
45 hepatoid adenocarcinoma 10.2 AFP ALB CDX2
46 ovarian clear cell carcinoma 10.2 GPC3 KRT7 NAPSA
47 gastric squamous cell carcinoma 10.2 ENO2 KRT7 SERPINA3
48 duodenum adenocarcinoma 10.2 CDX2 KRT7
49 acinar cell carcinoma 10.2 AFP KRT7 SERPINA1
50 embryonal sarcoma 10.2 GPC3 MDM2 SERPINA3

Graphical network of the top 20 diseases related to Testicular Malignant Germ Cell Cancer:



Diseases related to Testicular Malignant Germ Cell Cancer

Symptoms & Phenotypes for Testicular Malignant Germ Cell Cancer

GenomeRNAi Phenotypes related to Testicular Malignant Germ Cell Cancer according to GeneCards Suite gene sharing:

27 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 AFP AHSG ALB CDX2 CEACAM5 ENO2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.83 AFP
3 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.83 AFP
4 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.83 POU5F1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.83 POU5F1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.83 KRT7
7 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.83 POU5F1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.83 AFP KRT7 POU5F1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.83 AFP
10 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.83 POU5F1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.83 AFP
12 Increased shRNA abundance (Z-score > 2) GR00366-A-65 9.83 AFP
13 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.83 KRT7 POU5F1

MGI Mouse Phenotypes related to Testicular Malignant Germ Cell Cancer:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.73 AFP AHSG ALB CDX2 F8 GPC3
2 digestive/alimentary MP:0005381 9.7 ALB CDX2 GPC3 MDM2 POU5F1 RUNX3
3 renal/urinary system MP:0005367 9.17 ALB GPC3 HP HPX KRT7 MDM2

Drugs & Therapeutics for Testicular Malignant Germ Cell Cancer

Drugs for Testicular Malignant Germ Cell Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 314)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
2
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
3
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
4
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2,Phase 3 5949-44-0
5
Testosterone enanthate Approved Phase 4,Phase 2,Phase 3 315-37-7 9416
6
Methyltestosterone Approved Phase 4,Phase 2,Phase 3 58-18-4 6010
7
Testosterone Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3 58-22-0, 481-30-1 10204 6013
8
Docetaxel Approved, Investigational Phase 4,Phase 2 114977-28-5 148124
9
Polyestradiol phosphate Approved Phase 4,Phase 3 28014-46-2
10
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3 50-28-2 5757
11
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
12 Immunologic Factors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
13 interferons Phase 4,Phase 1,Phase 2
14 Adjuvants, Immunologic Phase 4,Phase 3,Phase 1,Phase 2
15 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Not Applicable
16 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
19 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Interferon Inducers Phase 4,Phase 1,Phase 2
21 Androgens Phase 4,Phase 2,Phase 3
22 Anabolic Agents Phase 4,Phase 2,Phase 3
23 Testosterone 17 beta-cypionate Phase 4,Phase 2,Phase 3
24 Follicle Stimulating Hormone Phase 4
25 Estradiol 3-benzoate Phase 4,Phase 3
26 Estradiol 17 beta-cypionate Phase 4,Phase 3
27
Ifosfamide Approved Phase 3,Phase 1,Phase 2 3778-73-2 3690
28
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
29
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
30
Vinblastine Approved Phase 3 865-21-4 241903 13342
31
Granisetron Approved, Investigational Phase 3,Not Applicable 109889-09-0 3510
32
Mechlorethamine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 51-75-2 4033
33
Bleomycin Approved, Investigational Phase 3,Phase 2,Not Applicable 11056-06-7 5360373
34
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
35
Oxaliplatin Approved, Investigational Phase 3,Phase 2 61825-94-3 43805 6857599 5310940 9887054
36
Lenograstim Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 135968-09-1
37
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 1177-87-3
38
Mesna Approved, Investigational Phase 3,Phase 1,Phase 2 3375-50-6 598
39
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 50-02-2 5743
40
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
41
Ofloxacin Approved Phase 3 82419-36-1 4583
42
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
43
Captopril Approved Phase 3 62571-86-2 44093
44
Ribavirin Approved Phase 3 36791-04-5 37542
45
Palivizumab Approved, Investigational Phase 3 188039-54-5
46
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
47
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
48
Itraconazole Approved, Investigational Phase 3,Not Applicable 84625-61-6 55283
49
Caspofungin Approved Phase 3,Phase 2 162808-62-0, 179463-17-3 2826718 468682
50
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956

Interventional clinical trials:

(show top 50) (show all 296)
# Name Status NCT ID Phase Drugs
1 Taste, Smell and Chemotherapy (TASTY) Completed NCT01641172 Phase 4
2 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4 Imiquimod
3 Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters Recruiting NCT03203681 Phase 4 NATESTO® (4.5% nasal testosterone) Nasal Gel
4 Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
5 Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors Unknown status NCT00002566 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;ifosfamide;vinblastine sulfate
6 Magnetic Resonance Imaging and Computed Tomography in Patients With Stage I Seminoma of the Testicle Unknown status NCT00589537 Phase 3
7 Lerisetron Compared With Granisetron in Preventing Nausea and Vomiting in Men Being Treated With Radiation Therapy for Stage I Seminoma Unknown status NCT00004219 Phase 3 granisetron hydrochloride;lerisetron
8 Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors Unknown status NCT00104676 Phase 3 cisplatin;etoposide;ifosfamide;oxaliplatin;paclitaxel
9 Combination Chemotherapy in Treating Men With Germ Cell Cancer Unknown status NCT00003643 Phase 2, Phase 3 cisplatin;etoposide;paclitaxel
10 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
11 Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors Unknown status NCT00274950 Phase 3 carboplatin;cisplatin;etoposide;ifosfamide;vinblastine sulfate
12 Radiation Therapy Compared With Chemotherapy in Treating Patients With Stage I Testicular Cancer Completed NCT00003014 Phase 3 carboplatin
13 Bleomycin, Etoposide, and Cisplatin in Treating Patients With Metastatic Germ Cell Cancer of the Testicles Completed NCT00324298 Phase 3 cisplatin;etoposide
14 Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors Completed NCT00002596 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide
15 Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors Completed NCT00053352 Phase 3 cisplatin;etoposide
16 Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer Completed NCT00003941 Phase 3 cisplatin;etoposide;ifosfamide
17 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
18 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
19 Androgen for Leydig Cell Proliferation Completed NCT01206270 Phase 2, Phase 3 Testosterone undecanoate;Castor Oil
20 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
21 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
22 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
23 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
24 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
25 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
26 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
27 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
28 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3 sodium thiosulfate
29 Study of Testosterone vs Placebo in Testicular Cancer Survivors Recruiting NCT02991209 Phase 2, Phase 3 Testosterone;Placebos
30 Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer Recruiting NCT02341989 Phase 3 Bleomycin Etoposide and Cisplatin;Carboplatin
31 Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours Recruiting NCT02582697 Phase 3 Bleomycin (active name: Bleomycin Sulfate);Etoposide;Cisplatin;Pegylated G-CSF (Pegfilgrastim);Filgrastim
32 Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors Recruiting NCT02375204 Phase 3 paclitaxel;ifosfamide;cisplatin;pegylated G-CSF;G-CSF;carboplatin;etoposide phosphate
33 Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours Active, not recruiting NCT01726374 Phase 3 BEP(500)
34 Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate Active, not recruiting NCT01444820 Phase 3
35 Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors Terminated NCT00072215 Phase 3 cisplatin;ifosfamide;paclitaxel;vinblastine
36 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
37 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
38 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
39 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Unknown status NCT01883518 Phase 1, Phase 2
40 Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy Unknown status NCT00772694 Phase 2 sorafenib
41 Effectiveness of an Individualized Program of Muscular Strength and Endurance Program for Improving Germ Cell Cancer Unknown status NCT02433197 Phase 1, Phase 2
42 Peptide Vaccination in Treating Patients With Esophageal Cancer (STF-II) Unknown status NCT01267578 Phase 2
43 A Study With Peptide Vaccination in Treating Patients With Esophageal Cancer Unknown status NCT00995358 Phase 2
44 Phase II Study of S-488410 to Treat Non-small Cell Lung Cancer Unknown status NCT01592617 Phase 2 S-488410
45 Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation Unknown status NCT01758367 Phase 1, Phase 2 Deciatbine(DAC)
46 Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors Unknown status NCT01743482 Phase 2 Pazopanib
47 Promotora-based Latino Family CVD Risk Reduction Unknown status NCT01714271 Phase 2
48 Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors Unknown status NCT00551122 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;ifosfamide;paclitaxel
49 Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors Unknown status NCT00127049 Phase 2 gemcitabine, ifosfamide, cisplatin, G-CSF
50 High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy Unknown status NCT01172912 Phase 2 carboplatin;cisplatin;dexamethasone;etoposide;ifosfamide

Search NIH Clinical Center for Testicular Malignant Germ Cell Cancer

Genetic Tests for Testicular Malignant Germ Cell Cancer

Anatomical Context for Testicular Malignant Germ Cell Cancer

MalaCards organs/tissues related to Testicular Malignant Germ Cell Cancer:

42
Testis, Bone Marrow, T Cells, Kidney, Ovary, Brain, Lymph Node

Publications for Testicular Malignant Germ Cell Cancer

Variations for Testicular Malignant Germ Cell Cancer

Expression for Testicular Malignant Germ Cell Cancer

Search GEO for disease gene expression data for Testicular Malignant Germ Cell Cancer.

Pathways for Testicular Malignant Germ Cell Cancer

GO Terms for Testicular Malignant Germ Cell Cancer

Cellular components related to Testicular Malignant Germ Cell Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 collagen-containing extracellular matrix GO:0062023 9.8 AHSG GPC3 HPX SERPINA1 SERPINA3
2 blood microparticle GO:0072562 9.65 AHSG ALB HP HPX SERPINA3
3 extracellular space GO:0005615 9.65 AFP AHSG ALB ENO2 F8 HP
4 endoplasmic reticulum lumen GO:0005788 9.63 AFP AHSG ALB F8 GPC3 SERPINA1
5 endocytic vesicle lumen GO:0071682 9.43 HP HPX
6 platelet alpha granule lumen GO:0031093 9.02 AHSG ALB F8 SERPINA1 SERPINA3
7 extracellular exosome GO:0070062 10.07 AHSG ALB CEACAM5 ENO2 HP HPX
8 extracellular region GO:0005576 10.06 AFP AHSG ALB CEACAM5 F8 GPC3

Biological processes related to Testicular Malignant Germ Cell Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.65 AFP AHSG ALB GPC3 SERPINA1
2 platelet degranulation GO:0002576 9.55 AHSG ALB F8 SERPINA1 SERPINA3
3 somatic stem cell population maintenance GO:0035019 9.5 CDX2 POU5F1 SALL4
4 cellular protein metabolic process GO:0044267 9.43 AFP AHSG ALB GPC3 NAPSA SERPINA1
5 acute-phase response GO:0006953 9.02 AHSG F8 HP SERPINA1 SERPINA3

Sources for Testicular Malignant Germ Cell Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....